Abstract
ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Autoimmune Diseases / drug therapy*
-
Autoimmune Diseases / immunology
-
Clinical Trials as Topic
-
Crohn Disease / drug therapy*
-
Crohn Disease / immunology
-
Drug Evaluation, Preclinical
-
Humans
-
Interleukin-12 / immunology*
-
Interleukin-13 / immunology*
-
Psoriasis / drug therapy
-
Psoriasis / immunology
-
Structure-Activity Relationship
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Interleukin-13
-
Interleukin-12
-
briakinumab